Patient Age/Gender: 60 years Male Printed: 03-Dec-18 11:35:00

| Procedure | Result | Units | Ref Interval | Reported/ Accession Collected Received Verified |
|-------------------------------|--------|-------|--------------|--|
| Carisoprodol, Serum or Plasma | 8.1 H | ug/mL | [0.0-8.0] | 18-337-900065 03-Dec-18 03-Dec-18 03-Dec-18 |
| - | | 5. | | 11:27:00 11:27:00 11:31:13 |
| Meprobamate, Serum or Plasma | 21.1 н | ug/mL | [5.0-20.0] | 18-337-900065 03-Dec-18 03-Dec-18 03-Dec-18 |
| _ | | - | | 11:27:00 11:27:00 11:31:13 |

03-Dec-18 11:27:00 Carisoprodol, Serum or Plasma: INTERPRETIVE INFORMATION: Carisoprodol and Meprobamate, Ser/Pla

Therapeutic Range: Less than 8.0 ug/mL Toxic: Greater than or equal to 8.0 ug/mL

The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Adverse effects may include drowsiness, dizziness and headache.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

03-Dec-18 11:27:00 Meprobamate, Serum or Plasma: INTERPRETIVE INFORMATION: Meprobamate, Serum or Plasma

Therapeutic Range: 5.0-20.0 ug/mL Toxic: Greater than 40.0 ug/mL

The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Adverse effects may include drowsiness, dizziness and headache.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS